Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2017-003496-54-DE
EUCTR2017-003496-54-DEActive, not recruitingPhase 1

A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH) - FOOTPATH

niversity Hospital, LMU Munich (Germany)0 sites270 target enrollmentStarted: August 16, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
270
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Adult patients = 18 years of age and = 75 years
  • •Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1]
  • •No option for surgical resection or radiation in curative intent
  • •At least one unidimensionally measurable tumor lesion (according to RECIST 1.1)
  • •ECOG performance status 0 - 1
  • •Life expectancy at least 3 months
  • •Adequate hepatic, renal and bone marrow function, defined as:
  • •- Absolute neutrophil count (ANC) = 2.0 x 109/L
  • •- Haemoglobin = 9 g/dL
  • •- Thrombocytes = 100 x 109/L
  • •- Total bilirubin = 1.5 x ULN. Patients with a biliary stent may be included provided that bilirubin level after stent insertion decreased to = 1.5 x ULN and there is no cholangitis.
  • •- AST/GOT and/or ALT/GPT = 2.5 x ULN or in case of liver
  • •metastasis = 5 x ULN)
  • •- Serum creatinine within normal limits or creatinine clearance = 60 mL/min/1.73 m2 as calculated by CKD-EPI formula for patients with serum creatinine levels above or below the institutional normal value.
  • •Females of childbearing potential (FCBP) must have a negative highly sensitive serum pregnancy test within 7 days of the first administration of study treatment and must agree to undergo a further pregnancy tests at monthly intervals and at the end of treatment visit
  • •FCBP must agree to use and be able to take highly effective contraceptive birth control methods (Pearl Index < 1) during the course of the study and for at least 1 month after last administration of study treatment. Complete sexual abstinence is acceptable as a highly effective contraceptive method only if the subject is refraining
  • •from heterosexual intercourse during the entire study treatment and at least one month after the discontinuation of study treatment and the reliability of sexual abstinence is in line with the preferred and usual lifestyle of the subject.
  • •A female subject following menarche is considered to be of childbearing potential unless she is naturally amenorrhoeic for = 1 year without an alternative medical reason, or unless she is permanently sterile.
  • •Males must agree to use condoms during the course of the trial and for at least 6 months after last administration of study drugs or practice complete abstinence from heterosexual intercourse.
  • •Signed and dated informed consent before the start of any specific protocol procedures
  • •Patient’s legal capacity to consent to study participation
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Locally advanced PDAC without metastasis
  • •Symptomatic/clinically significant ascites (expected indication for repeated paracentesis)
  • •Known metastatic disease to the brain. Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
  • •Previous palliative chemotherapy or other palliative systemic tumor therapy for metastatic disease of PDAC
  • •Previous gemcitabine or 5-FU based treatment with exception of gemcitabine/fluoropyrimidine based treatment applied in the neoadjuvant or adjuvant setting (before/after potential curative R0 or R1 resection) and if the neoadjuvant/adjuvant chemotherapy was terminated at least 6 months before randomization
  • •Previous radiotherapy of PDAC with exception of radiotherapy in the context of a neoadjuvant or adjuvant treatment setting that was terminated at least 6 months before randomization
  • •Any major surgery within the last 4 weeks before randomization
  • •Clinically significant decrease in performance status within 2 weeks of intended first administration of study medication (by medical history)
  • •Severe tumor-related cachexia and/or known weight loss > 15% within one month before study enrollment
  • •Pre-existing polyneuropathy = grade 2 according to CTCAE version 5.0
  • •Chronic intestinal diseases and gastrointestinal disorders with diarrhoea as a major symptom (e.g. Crohn’s disease, malabsorption), and chronic diarrhoea of any aetiology CTCAE version 5.0 grade ? 2
  • •Any other severe concomitant disease or disorder, which could influence patient’s ability to participate in the study and his/her safety during the study or interfere with interpretation of study results e.g. active infection, uncontrolled hypertension, clinically significant cardiovascular disease e.g. cerebrovascular accident (= 6 months before study start), myocardial infarction (= 6 months before study start), unstable angina, heart failure = NYHA functional classification system grade 2, severe cardiac arrhythmia requiring medication, metabolic dysfunction, severe renal disorder.
  • •Any other malignancies than PDAC within the last 5 years before study start, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer
  • •Hypersensitivity to the study drugs or to any of the excipients or to compounds with similar chemical or biologic composition
  • •Use of strong CYP3A4 inhibitors (CYP3A4 inhibitors have to be discontinued at least one week prior to start of study treatment). Use of strong UGT1A1 inhibitors or strong CYP3A4 inducers unless there are no therapeutic alternatives.
  • •Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required)
  • •Known complete DPD deficiency (specific screening according to the recommendations of the SmPC in effect for 5-FU; patients with a known complete DPD deficiency must be excluded; patients with a known partial DPD deficiency may be included at the discretion of the investigator)
  • •Treatment with nucleoside analogues including sorivudine or brivudine within 28 days before study enrollment or requirement for concomitant antiviral treatment with sorivudine or brivudine or analogues
  • •Continuing abuse of alcohol, drugs, or medical drugs
  • •Pregnant or breast-feeding females or FCBPs unable to either perform highly effective contraceptive measures or practice complete abstinence from heterosexual intercourse
  • •Current or recent treatment with an investigati

Investigators

Sponsor
niversity Hospital, LMU Munich (Germany)

Similar Trials

Active, not recruiting
Phase 1
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
EUCTR2024-000203-67-Outside-EU/EEAKadmon Corporation, LLC
Not yet recruiting
Phase 2
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck CancerOral MucositisHead and Neck CancerCancer - Head and neckOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12620000540910PSI CRO Australia Pty. Ltd.110
Active, not recruiting
Not Applicable
A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic Lymphocytic Leukemia (CLL) -Chronic Lymphocytic Leukemia (CLL)
EUCTR2004-000440-24-SECephalon UK Limited80
Active, not recruiting
Phase 1
A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving treatment with 5-FU, leucovorin, oxaliplatin and bevacizumab with or without irinotecan as first line treatment
EUCTR2007-007863-26-FRF. Hoffmann-La Roche Ltd80
Active, not recruiting
Not Applicable
A study with bevacizumab in combination with standard of care treatment (mFOLFOX-6 or FOLFOXIRI) to assess the safety and the possibility to surgically remove liver metastasis (spread of the disease to the liver) in patients with inoperable liver metastasis secondary to bowel cancer.
EUCTR2007-007863-26-ATF. Hoffmann-La Roche Ltd80